Analyst Ratings for Replimune Group
Replimune Group (NASDAQ:REPL) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
12 Health Care Stocks Moving In Monday’s Intraday Session
Gainers INVO Bioscience (NASDAQ:INVO) stock rose 50.9% to $0.32 during Monday’s regular session. Trading volume for this security…
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding.
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
HC Wainwright & Co. Reiterates Buy on Replimune Group, Raises Price Target to $50
HC Wainwright & Co. analyst Robert Burns reiterates Replimune Group (NASDAQ:REPL) with a Buy and raises the price target from $48 to $50.
Analyst Beefs Up Replimune Price Target As Recent Data Validates Treatment Platform
Last Thursday, Replimune Group Inc (NASDAQ: REPL) announced an initial data snapshot from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical.
BMO Capital Maintains Outperform on Replimune Group, Raises Price Target to $70
BMO Capital analyst Evan David Seigerman maintains Replimune Group (NASDAQ:REPL) with a Outperform and raises the price target from $40 to $70.
Reported Late Thursday, Replimune Announces Pricing Of $225M Public Offering Of 5,374,486 Shares Of Common Stock At A Price Of $23.50/Share
Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering
Analyst Ratings for Replimune Group
Replimune Group (NASDAQ:REPL) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
SVB Leerink Maintains Outperform on Replimune Group, Raises Price Target to $34
SVB Leerink analyst Jonathan Chang maintains Replimune Group (NASDAQ:REPL) with a Outperform and raises the price target from $30 to $34.